University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT04323189
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
This study is active but is not currently recruiting participants.
18 year–80 year
All sexes
Interventional
Phase 4
Philadelphia, Pennsylvania, 19104, United States
Participants of this pilot clinical trial will be randomized in a blinded 2:2 crossover manner to receive placebo and sitagliptin 100 mg/d (DPP4 inhibitor), in random order. Subjects will receive each intervention for seven days, with a study day on day 7. Each intervention will be separated by a 4-week washout period. Each subject will have up to four separate visits: 1) DXA, echocardiogram, 2) cardiac MRI, 3) mixed meal during placebo, 4) mixed meal during sitagliptin.
The study will include 10 cases (heterozygous for DPP4 loss of function variant) and 10 controls.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sitagliptin will be administered daily for 7 days, with a study day on day 7.
Other names: Januvia
Placebo will be administered daily for 7 days, with a study day on day 7.
Time frame: during study days 1 and 2
DPP4 activity and antigen concentration
Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
Glucose will be measured before after the mixed meal during sitagliptin and placebo. Area under the curve will be calculated based on at least 10 time points after the meal.
Time frame: Calculated from samples collected before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
Disposition index will be calculated from insulin sensitivity and insulin secretion. These variables will be computed using mathematical modeling of insulin and c-peptide. We will collect insulin and c-peptide at least 10 time points after the meal.
Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
Measured via an automated blood pressure cuff approximately every 15 minutes
Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
This is released in response to a meal and rapidly degraded by DPP4. We will collect samples for at least six time points after the meal.
Time frame: Before the meal or at baseline (t=-15 or -1 min) on study days 1 and 2
CD26 is DPP4 on T cells and monocytes.
Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
Triglycerides, free fatty acids; We will collect samples at least six time points after the meal.
Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2
Measured via an automated blood pressure cuff approximately every 15 minutes
University of Pennsylvania
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05205356
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mobile, Alabama, United States
View Trial DetailsNCT06057181
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes
Fort Wayne, Indiana, United States
View Trial DetailsNCT03717194
Cardiovascular Diseases, Diabetes Mellitus
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT03939624
All-Cause Mortality, Brain Diseases
Montreal, Quebec, Canada
View Trial Details